Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.3K
Overview
51.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

363
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
363
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.0K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.0K
Cancer Vaccines01:30

Cancer Vaccines

990
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
990
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

507
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
507
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

414
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
414

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Checkpoint inhibitors create rogue regulatory T cells.

The Journal of clinical investigation·2026
Same author

Immunometabolic remodeling of perivascular adipose tissue in murine lupus: implications for lupus vasculopathy.

bioRxiv : the preprint server for biology·2026
Same author

scDIG: An R Shiny Application for Interactive Density-Based Gating of Single-Cell Proteomic and Transcriptomic Data.

bioRxiv : the preprint server for biology·2026
Same author

CD8<sup>+</sup> T cells in atherosclerosis and coronary artery disease.

Nature reviews. Cardiology·2026
Same author

A poorly reactogenic lipid nanoparticle-mRNA vaccine unveils an innate immune pathway for adverse reactions.

NPJ vaccines·2026
Same author

IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner.

NPJ vaccines·2026

Related Experiment Video

Updated: Jan 27, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

40.2K

Vaccination against atherosclerosis.

Kouji Kobiyama1, Ryosuke Saigusa1, Klaus Ley2

  • 1Division of Inflammation Biology, La Jolla Institute for Immunology, La Jolla, CA, United States.

Current Opinion in Immunology
|April 1, 2019
PubMed
Summary

Atherosclerosis vaccines targeting inflammatory risk are promising. This review explores antibody-inducing and regulatory T cell-inducing vaccines for long-term protection against cardiovascular events.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.7K
Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis
09:55

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis

Published on: October 25, 2024

1.5K

Related Experiment Videos

Last Updated: Jan 27, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

40.2K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.7K
Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis
09:55

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis

Published on: October 25, 2024

1.5K

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Vaccinology

Background:

  • Atherosclerosis is a leading cause of global mortality, characterized by chronic inflammation and significant residual cardiovascular risk despite statin therapy.
  • The autoimmune component of atherosclerosis presents an opportunity for immunologic interventions, particularly vaccination.
  • Current treatments leave a residual inflammatory risk, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review the potential of vaccination as an immunologic approach to combat atherosclerosis.
  • To focus on two distinct vaccine strategies: antibody-inducing and regulatory T cell-inducing vaccines.
  • To highlight candidate antigens and their efficacy in preclinical atherosclerosis models.

Main Methods:

  • Review of existing literature on atherosclerosis, immunology, and vaccine development.
  • Analysis of preclinical studies investigating atherosclerosis vaccine candidates in animal models.
  • Categorization of vaccines based on their immunologic mechanism (antibody-inducing vs. regulatory T cell-inducing).

Main Results:

  • Several candidate antigens have been identified for atherosclerosis vaccine development.
  • Vaccine strategies targeting atherosclerosis have demonstrated efficacy in reducing disease progression in animal models.
  • Two primary vaccine-induced immune responses are discussed: antibody induction and regulatory T cell induction.

Conclusions:

  • Vaccination offers a specific, non-immunosuppressive, and potentially long-lasting approach to managing atherosclerosis.
  • Both antibody-inducing and regulatory T cell-inducing vaccines represent viable strategies for mitigating atherosclerosis.
  • Further research into atherosclerosis vaccines could significantly reduce the global burden of cardiovascular disease.